| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 25 | 2022 | 1213 | 2.570 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 8 | 2024 | 153 | 2.240 |
Why?
|
| Membrane Proteins | 9 | 2024 | 909 | 1.660 |
Why?
|
| Plant Extracts | 5 | 2018 | 174 | 1.610 |
Why?
|
| Mammary Glands, Animal | 11 | 2022 | 79 | 1.550 |
Why?
|
| Estrogens | 6 | 2020 | 116 | 1.490 |
Why?
|
| Food Hypersensitivity | 8 | 2025 | 25 | 1.400 |
Why?
|
| Breast | 5 | 2024 | 190 | 1.380 |
Why?
|
| Rhodiola | 5 | 2018 | 15 | 1.370 |
Why?
|
| Mast Cells | 8 | 2025 | 39 | 1.320 |
Why?
|
| Epithelial Cells | 8 | 2022 | 401 | 1.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2020 | 534 | 1.120 |
Why?
|
| Macrophages | 4 | 2024 | 1053 | 1.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2024 | 343 | 0.920 |
Why?
|
| Mammary Glands, Human | 5 | 2019 | 55 | 0.920 |
Why?
|
| Phytotherapy | 3 | 2018 | 51 | 0.860 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2017 | 85 | 0.790 |
Why?
|
| Biomarkers, Tumor | 6 | 2020 | 512 | 0.770 |
Why?
|
| DNA Methylation | 4 | 2020 | 294 | 0.770 |
Why?
|
| Cell Proliferation | 11 | 2020 | 1001 | 0.770 |
Why?
|
| Wnt Signaling Pathway | 4 | 2024 | 82 | 0.760 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 15 | 0.750 |
Why?
|
| Mammary Neoplasms, Animal | 3 | 2022 | 29 | 0.740 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2022 | 39 | 0.730 |
Why?
|
| Mice | 29 | 2025 | 11003 | 0.710 |
Why?
|
| Milk, Human | 4 | 2022 | 91 | 0.690 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2021 | 309 | 0.660 |
Why?
|
| Macrophage Activation | 1 | 2020 | 119 | 0.640 |
Why?
|
| Proteins | 2 | 2017 | 760 | 0.630 |
Why?
|
| Female | 41 | 2024 | 33382 | 0.610 |
Why?
|
| Environmental Exposure | 2 | 2020 | 220 | 0.600 |
Why?
|
| Animals | 33 | 2025 | 20962 | 0.580 |
Why?
|
| Receptors, Estrogen | 5 | 2020 | 130 | 0.580 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2024 | 617 | 0.580 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 666 | 0.570 |
Why?
|
| Interleukin-10 | 4 | 2025 | 161 | 0.570 |
Why?
|
| Early Growth Response Protein 2 | 1 | 2017 | 8 | 0.540 |
Why?
|
| Disease Models, Animal | 10 | 2025 | 2238 | 0.520 |
Why?
|
| Cell Line, Tumor | 10 | 2020 | 1494 | 0.520 |
Why?
|
| Mice, Inbred BALB C | 11 | 2024 | 891 | 0.510 |
Why?
|
| Transforming Growth Factor beta | 3 | 2017 | 174 | 0.500 |
Why?
|
| Obesity | 5 | 2020 | 1248 | 0.490 |
Why?
|
| Mammaplasty | 2 | 2014 | 49 | 0.480 |
Why?
|
| Immunoglobulin E | 6 | 2025 | 82 | 0.480 |
Why?
|
| Signal Transduction | 8 | 2025 | 3070 | 0.470 |
Why?
|
| Melanoma, Experimental | 1 | 2015 | 44 | 0.450 |
Why?
|
| Transcriptome | 6 | 2020 | 396 | 0.450 |
Why?
|
| Humans | 42 | 2024 | 64279 | 0.440 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 14 | 0.430 |
Why?
|
| Energy Metabolism | 1 | 2017 | 384 | 0.430 |
Why?
|
| Mice, Knockout | 9 | 2025 | 2140 | 0.420 |
Why?
|
| Leukocytes | 1 | 2014 | 103 | 0.410 |
Why?
|
| Phenols | 2 | 2018 | 82 | 0.400 |
Why?
|
| Inflammation | 4 | 2024 | 1162 | 0.400 |
Why?
|
| Glioblastoma | 1 | 2015 | 159 | 0.400 |
Why?
|
| Adiposity | 1 | 2013 | 83 | 0.390 |
Why?
|
| Progesterone | 3 | 2008 | 163 | 0.390 |
Why?
|
| Apoptosis | 4 | 2020 | 1094 | 0.380 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 303 | 0.370 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 313 | 0.360 |
Why?
|
| Endocrine Disruptors | 3 | 2022 | 79 | 0.360 |
Why?
|
| Cytokines | 6 | 2025 | 944 | 0.340 |
Why?
|
| Parabens | 2 | 2021 | 6 | 0.340 |
Why?
|
| Glucose | 1 | 2013 | 471 | 0.330 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 3 | 2025 | 7 | 0.330 |
Why?
|
| Benzophenones | 2 | 2020 | 19 | 0.320 |
Why?
|
| Doxorubicin | 3 | 2016 | 101 | 0.310 |
Why?
|
| Prodrugs | 3 | 2016 | 36 | 0.310 |
Why?
|
| Cells, Cultured | 7 | 2021 | 2177 | 0.310 |
Why?
|
| Phosphorylcholine | 3 | 2016 | 44 | 0.300 |
Why?
|
| Triple Negative Breast Neoplasms | 3 | 2021 | 73 | 0.290 |
Why?
|
| Pregnancy | 6 | 2024 | 2370 | 0.280 |
Why?
|
| Interleukin-33 | 2 | 2025 | 18 | 0.280 |
Why?
|
| Tissue Culture Techniques | 2 | 2020 | 36 | 0.280 |
Why?
|
| Cell Respiration | 2 | 2018 | 21 | 0.270 |
Why?
|
| Cell Death | 1 | 2008 | 286 | 0.260 |
Why?
|
| beta Catenin | 3 | 2017 | 99 | 0.250 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 1621 | 0.240 |
Why?
|
| Immunohistochemistry | 4 | 2015 | 901 | 0.240 |
Why?
|
| Plant Roots | 2 | 2016 | 61 | 0.230 |
Why?
|
| Transcriptional Activation | 2 | 2016 | 191 | 0.220 |
Why?
|
| Spheroids, Cellular | 2 | 2016 | 27 | 0.220 |
Why?
|
| Receptors, Progesterone | 2 | 2015 | 110 | 0.210 |
Why?
|
| Lactation | 2 | 2022 | 70 | 0.210 |
Why?
|
| Interleukin-4 | 1 | 2024 | 146 | 0.210 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2014 | 48 | 0.210 |
Why?
|
| Intestines | 3 | 2020 | 169 | 0.210 |
Why?
|
| Antibodies, Neutralizing | 2 | 2024 | 214 | 0.210 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2022 | 63 | 0.200 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2014 | 151 | 0.200 |
Why?
|
| Diet, High-Fat | 2 | 2014 | 176 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2014 | 110 | 0.190 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2022 | 13 | 0.190 |
Why?
|
| Estrogen Receptor alpha | 3 | 2020 | 49 | 0.190 |
Why?
|
| Zeranol | 1 | 2022 | 1 | 0.180 |
Why?
|
| CpG Islands | 2 | 2020 | 216 | 0.180 |
Why?
|
| Gene Expression | 2 | 2022 | 851 | 0.180 |
Why?
|
| Adult | 12 | 2022 | 17133 | 0.180 |
Why?
|
| Polymers | 2 | 2016 | 327 | 0.180 |
Why?
|
| Breast Feeding | 2 | 2022 | 153 | 0.180 |
Why?
|
| Genes, Modifier | 1 | 2021 | 3 | 0.180 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2021 | 7 | 0.180 |
Why?
|
| Genes, Neoplasm | 1 | 2021 | 24 | 0.170 |
Why?
|
| Down-Regulation | 2 | 2013 | 319 | 0.170 |
Why?
|
| MCF-7 Cells | 3 | 2016 | 67 | 0.170 |
Why?
|
| Anti-Allergic Agents | 1 | 2020 | 4 | 0.170 |
Why?
|
| Phenotype | 2 | 2017 | 1222 | 0.170 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2020 | 15 | 0.170 |
Why?
|
| Young Adult | 5 | 2020 | 4781 | 0.170 |
Why?
|
| Middle Aged | 11 | 2022 | 17923 | 0.170 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 88 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 460 | 0.160 |
Why?
|
| Cell Polarity | 1 | 2020 | 109 | 0.160 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 158 | 0.150 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 391 | 0.150 |
Why?
|
| DNA Repair | 1 | 2021 | 250 | 0.150 |
Why?
|
| DNA Replication | 1 | 2021 | 241 | 0.150 |
Why?
|
| Gene Expression Profiling | 5 | 2019 | 783 | 0.150 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 373 | 0.150 |
Why?
|
| Environmental Pollutants | 1 | 2020 | 95 | 0.140 |
Why?
|
| Curcumin | 2 | 2020 | 82 | 0.140 |
Why?
|
| Mitochondria | 2 | 2012 | 384 | 0.140 |
Why?
|
| Neuroblastoma | 1 | 2018 | 53 | 0.140 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 61 | 0.140 |
Why?
|
| Quantitative Trait Loci | 1 | 2018 | 77 | 0.140 |
Why?
|
| Cell Degranulation | 3 | 2024 | 20 | 0.130 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 13 | 0.130 |
Why?
|
| Prognosis | 3 | 2020 | 1769 | 0.130 |
Why?
|
| Axin Protein | 2 | 2017 | 10 | 0.130 |
Why?
|
| Metabolomics | 1 | 2017 | 57 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 358 | 0.120 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 327 | 0.120 |
Why?
|
| Mice, 129 Strain | 1 | 2016 | 41 | 0.120 |
Why?
|
| Adolescent | 5 | 2021 | 6305 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 3450 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 231 | 0.120 |
Why?
|
| Mastocytosis | 1 | 2015 | 1 | 0.120 |
Why?
|
| Phosphorylation | 3 | 2015 | 948 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2015 | 614 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 3 | 2014 | 279 | 0.120 |
Why?
|
| Histones | 1 | 2018 | 486 | 0.110 |
Why?
|
| Transforming Growth Factor beta2 | 1 | 2015 | 8 | 0.110 |
Why?
|
| Anaphylaxis | 1 | 2015 | 40 | 0.110 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2014 | 7 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2014 | 31 | 0.110 |
Why?
|
| Oxidative Phosphorylation | 2 | 2012 | 41 | 0.110 |
Why?
|
| Aged | 7 | 2021 | 14664 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 155 | 0.110 |
Why?
|
| RANK Ligand | 1 | 2014 | 22 | 0.110 |
Why?
|
| Mutation | 2 | 2021 | 2629 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 209 | 0.110 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2014 | 18 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2013 | 68 | 0.110 |
Why?
|
| DNA, Neoplasm | 1 | 2014 | 59 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 72 | 0.110 |
Why?
|
| Parity | 1 | 2014 | 71 | 0.100 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2013 | 9 | 0.100 |
Why?
|
| Gene Deletion | 1 | 2015 | 312 | 0.100 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2013 | 20 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 56 | 0.100 |
Why?
|
| Ovary | 1 | 2013 | 101 | 0.100 |
Why?
|
| Ovalbumin | 3 | 2020 | 116 | 0.100 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2013 | 27 | 0.100 |
Why?
|
| Dietary Fats | 1 | 2014 | 175 | 0.100 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2013 | 29 | 0.100 |
Why?
|
| Adipose Tissue, White | 1 | 2013 | 87 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 132 | 0.100 |
Why?
|
| Cell Line | 2 | 2015 | 2055 | 0.100 |
Why?
|
| Biopsy | 1 | 2015 | 449 | 0.100 |
Why?
|
| Caspase 3 | 1 | 2013 | 108 | 0.100 |
Why?
|
| Lipogenesis | 1 | 2013 | 68 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2013 | 60 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2014 | 204 | 0.100 |
Why?
|
| Estradiol | 2 | 2018 | 258 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 518 | 0.100 |
Why?
|
| Infant | 3 | 2022 | 1664 | 0.100 |
Why?
|
| Fatty Liver | 1 | 2013 | 109 | 0.100 |
Why?
|
| Fluorocarbon Polymers | 1 | 2012 | 4 | 0.090 |
Why?
|
| Fluorobenzenes | 1 | 2012 | 6 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 195 | 0.090 |
Why?
|
| Methacrylates | 1 | 2012 | 40 | 0.090 |
Why?
|
| Zebrafish Proteins | 1 | 2013 | 159 | 0.090 |
Why?
|
| Muramidase | 1 | 2012 | 47 | 0.090 |
Why?
|
| Morphogenesis | 1 | 2012 | 114 | 0.090 |
Why?
|
| Body Weight | 1 | 2013 | 379 | 0.090 |
Why?
|
| Wnt Proteins | 1 | 2012 | 100 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 329 | 0.090 |
Why?
|
| Immunoglobulin A | 2 | 2022 | 98 | 0.090 |
Why?
|
| DNA Damage | 1 | 2013 | 289 | 0.090 |
Why?
|
| Electron Transport Complex I | 1 | 2011 | 15 | 0.090 |
Why?
|
| Zinc Finger E-box Binding Homeobox 2 | 1 | 2011 | 1 | 0.090 |
Why?
|
| Organ Culture Techniques | 2 | 2008 | 70 | 0.090 |
Why?
|
| Homeostasis | 1 | 2013 | 370 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 43 | 0.090 |
Why?
|
| Telomerase | 1 | 2011 | 29 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 46 | 0.080 |
Why?
|
| Disease Progression | 2 | 2019 | 1176 | 0.080 |
Why?
|
| Quinolines | 1 | 2011 | 48 | 0.080 |
Why?
|
| Pyrroles | 1 | 2011 | 52 | 0.080 |
Why?
|
| Cell Movement | 2 | 2013 | 466 | 0.080 |
Why?
|
| Th2 Cells | 2 | 2024 | 98 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 212 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 205 | 0.080 |
Why?
|
| Pyrazoles | 1 | 2011 | 87 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 463 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2016 | 697 | 0.080 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2009 | 5 | 0.080 |
Why?
|
| Insulin | 1 | 2013 | 686 | 0.080 |
Why?
|
| Carcinogenesis | 2 | 2022 | 131 | 0.080 |
Why?
|
| Time Factors | 1 | 2017 | 3726 | 0.080 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 78 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 272 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 141 | 0.070 |
Why?
|
| Repressor Proteins | 1 | 2011 | 348 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2008 | 11 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2008 | 49 | 0.070 |
Why?
|
| NF-kappa B | 3 | 2018 | 471 | 0.070 |
Why?
|
| Wound Healing | 1 | 2009 | 192 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2008 | 60 | 0.070 |
Why?
|
| Rats | 2 | 2022 | 2005 | 0.070 |
Why?
|
| Diarrhea | 2 | 2020 | 76 | 0.070 |
Why?
|
| Random Allocation | 1 | 2008 | 201 | 0.070 |
Why?
|
| Reference Values | 1 | 2008 | 333 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 162 | 0.070 |
Why?
|
| Genome, Human | 1 | 2009 | 240 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2013 | 1551 | 0.070 |
Why?
|
| Caspases | 1 | 2008 | 176 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 165 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 544 | 0.060 |
Why?
|
| Risk Factors | 4 | 2020 | 5342 | 0.060 |
Why?
|
| Cell Survival | 2 | 2018 | 582 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2020 | 685 | 0.060 |
Why?
|
| Cyclin D1 | 2 | 2017 | 16 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1164 | 0.060 |
Why?
|
| Risk | 2 | 2016 | 379 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 1683 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2015 | 5697 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2024 | 37 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 5528 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 883 | 0.050 |
Why?
|
| Spleen | 1 | 2024 | 483 | 0.050 |
Why?
|
| Receptors, CCR7 | 1 | 2022 | 9 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 61 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2022 | 115 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1131 | 0.050 |
Why?
|
| Half-Life | 2 | 2012 | 79 | 0.050 |
Why?
|
| Rodentia | 1 | 2022 | 22 | 0.050 |
Why?
|
| Breast Density | 1 | 2022 | 17 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 100 | 0.050 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2022 | 8 | 0.050 |
Why?
|
| Caprylates | 1 | 2022 | 14 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 60 | 0.040 |
Why?
|
| Environment | 1 | 2022 | 123 | 0.040 |
Why?
|
| Phthalic Acids | 1 | 2022 | 40 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 116 | 0.040 |
Why?
|
| Ethiopia | 1 | 2021 | 9 | 0.040 |
Why?
|
| Fluorocarbons | 1 | 2022 | 44 | 0.040 |
Why?
|
| Genetic Linkage | 1 | 2021 | 96 | 0.040 |
Why?
|
| Recombinational DNA Repair | 1 | 2021 | 25 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2024 | 572 | 0.040 |
Why?
|
| Maternal Exposure | 1 | 2021 | 42 | 0.040 |
Why?
|
| Bacitracin | 1 | 2020 | 5 | 0.040 |
Why?
|
| Rutin | 1 | 2020 | 5 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2021 | 116 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2022 | 207 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 210 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 8 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2022 | 625 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2021 | 290 | 0.040 |
Why?
|
| Folic Acid | 1 | 2020 | 42 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2020 | 17 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2024 | 645 | 0.040 |
Why?
|
| Toxicity Tests | 1 | 2020 | 18 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 329 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 371 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 89 | 0.040 |
Why?
|
| Hydroxamic Acids | 1 | 2018 | 28 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 497 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 36 | 0.040 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2018 | 10 | 0.040 |
Why?
|
| Acetylation | 1 | 2018 | 123 | 0.040 |
Why?
|
| Cytotoxins | 1 | 2018 | 12 | 0.040 |
Why?
|
| Mastectomy | 1 | 2018 | 58 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 230 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 161 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 237 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 147 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2022 | 1375 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 423 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2017 | 39 | 0.030 |
Why?
|
| Epithelium | 2 | 2008 | 96 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 874 | 0.030 |
Why?
|
| Receptors, IgE | 1 | 2016 | 5 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 40 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2016 | 149 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2018 | 297 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 325 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 2019 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2018 | 387 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 271 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 2605 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 517 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 526 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 91 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2015 | 199 | 0.030 |
Why?
|
| Serine | 1 | 2014 | 91 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 727 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1431 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 263 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 761 | 0.030 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2013 | 6 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 375 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 243 | 0.020 |
Why?
|
| Carcinogens, Environmental | 1 | 2012 | 6 | 0.020 |
Why?
|
| Transfection | 1 | 2014 | 695 | 0.020 |
Why?
|
| Micrococcus | 1 | 2012 | 3 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 396 | 0.020 |
Why?
|
| Esters | 1 | 2012 | 19 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2012 | 47 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 759 | 0.020 |
Why?
|
| Polymerization | 1 | 2012 | 36 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2012 | 190 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 149 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 296 | 0.020 |
Why?
|
| Child | 1 | 2021 | 4583 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2011 | 32 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 618 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 402 | 0.020 |
Why?
|
| Particle Size | 1 | 2012 | 421 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1570 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2621 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 1332 | 0.020 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2008 | 16 | 0.020 |
Why?
|
| 14-3-3 Proteins | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 99 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2008 | 103 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 302 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1997 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 297 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2738 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2005 | 150 | 0.010 |
Why?
|
| Male | 1 | 2024 | 30323 | 0.010 |
Why?
|
| Neoplasms | 1 | 2011 | 1392 | 0.010 |
Why?
|